Jointown Pharmaceutical Group Co., Ltd (SHA:600998)
China
· Delayed Price · Currency is CNY 5.24
+0.02 (0.38%)
May 13, 2025, 3:00 PM CST
SHA:600998 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 153,239 | 151,695 | 149,981 | 140,282 | 122,359 | 110,819 | Upgrade
|
| Other Revenue | 115.13 | 115.13 | 158.54 | 142.16 | 48.09 | 40.49 | Upgrade
|
| Revenue | 153,354 | 151,810 | 150,140 | 140,424 | 122,407 | 110,860 | Upgrade
|
| Revenue Growth (YoY) | 3.26% | 1.11% | 6.92% | 14.72% | 10.42% | 11.42% | Upgrade
|
| Cost of Revenue | 141,454 | 140,075 | 138,140 | 129,560 | 112,636 | 100,981 | Upgrade
|
| Gross Profit | 11,900 | 11,735 | 12,000 | 10,864 | 9,772 | 9,879 | Upgrade
|
| Selling, General & Admin | 7,419 | 7,229 | 7,193 | 6,637 | 6,097 | 5,667 | Upgrade
|
| Research & Development | 138.58 | 146.7 | 196.61 | 178.39 | 194.94 | 126.63 | Upgrade
|
| Other Operating Expenses | 409.17 | 413.12 | 425.65 | 98.16 | 293.01 | 253.25 | Upgrade
|
| Operating Expenses | 7,999 | 7,813 | 7,947 | 7,074 | 6,684 | 6,155 | Upgrade
|
| Operating Income | 3,900 | 3,923 | 4,053 | 3,790 | 3,087 | 3,724 | Upgrade
|
| Interest Expense | -1,218 | -1,284 | -1,318 | -1,221 | -1,145 | -1,027 | Upgrade
|
| Interest & Investment Income | 2,289 | 1,456 | 255.17 | 490.63 | 310.74 | 288.54 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.81 | -0.81 | -4.34 | -17.05 | -6.65 | -1.53 | Upgrade
|
| Other Non Operating Income (Expenses) | -138.62 | -138.58 | -265.43 | -281.66 | -151.72 | -155.5 | Upgrade
|
| EBT Excluding Unusual Items | 4,831 | 3,955 | 2,721 | 2,760 | 2,094 | 2,828 | Upgrade
|
| Impairment of Goodwill | -10.85 | -10.85 | -1.18 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -97.57 | -98.35 | -78.4 | 1.44 | 1,235 | 1,052 | Upgrade
|
| Gain (Loss) on Sale of Assets | -663.3 | -425.83 | 5.11 | 45.67 | 6.72 | 258.03 | Upgrade
|
| Asset Writedown | -25.95 | - | - | - | -2.35 | -0.69 | Upgrade
|
| Other Unusual Items | 217.45 | 217.45 | 344.62 | 30.9 | 29.12 | 196.12 | Upgrade
|
| Pretax Income | 4,251 | 3,637 | 2,991 | 2,838 | 3,363 | 4,334 | Upgrade
|
| Income Tax Expense | 992.88 | 851.03 | 701.2 | 552.55 | 754.88 | 948.94 | Upgrade
|
| Earnings From Continuing Operations | 3,258 | 2,786 | 2,290 | 2,286 | 2,608 | 3,385 | Upgrade
|
| Minority Interest in Earnings | -318.58 | -279.05 | -115.62 | -200.57 | -160.05 | -310.03 | Upgrade
|
| Net Income | 2,940 | 2,507 | 2,174 | 2,085 | 2,448 | 3,075 | Upgrade
|
| Net Income to Common | 2,940 | 2,507 | 2,174 | 2,085 | 2,448 | 3,075 | Upgrade
|
| Net Income Growth | 36.69% | 15.33% | 4.27% | -14.84% | -20.38% | 78.10% | Upgrade
|
| Shares Outstanding (Basic) | 5,069 | 5,015 | 5,056 | 5,274 | 5,187 | 5,172 | Upgrade
|
| Shares Outstanding (Diluted) | 5,069 | 5,015 | 5,056 | 5,274 | 5,187 | 5,339 | Upgrade
|
| Shares Change (YoY) | 1.69% | -0.81% | -4.14% | 1.68% | -2.84% | -3.46% | Upgrade
|
| EPS (Basic) | 0.58 | 0.50 | 0.43 | 0.40 | 0.47 | 0.59 | Upgrade
|
| EPS (Diluted) | 0.58 | 0.50 | 0.43 | 0.40 | 0.47 | 0.58 | Upgrade
|
| EPS Growth | 34.42% | 16.28% | 8.78% | -16.25% | -18.06% | 84.50% | Upgrade
|
| Free Cash Flow | 2,220 | 2,107 | 3,699 | 2,743 | 2,073 | 1,987 | Upgrade
|
| Free Cash Flow Per Share | 0.44 | 0.42 | 0.73 | 0.52 | 0.40 | 0.37 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.194 | 0.186 | 0.112 | 0.186 | Upgrade
|
| Dividend Growth | 3.20% | 3.20% | 4.31% | 66.64% | -39.99% | - | Upgrade
|
| Gross Margin | 7.76% | 7.73% | 7.99% | 7.74% | 7.98% | 8.91% | Upgrade
|
| Operating Margin | 2.54% | 2.58% | 2.70% | 2.70% | 2.52% | 3.36% | Upgrade
|
| Profit Margin | 1.92% | 1.65% | 1.45% | 1.49% | 2.00% | 2.77% | Upgrade
|
| Free Cash Flow Margin | 1.45% | 1.39% | 2.46% | 1.95% | 1.69% | 1.79% | Upgrade
|
| EBITDA | 4,593 | 4,612 | 4,730 | 4,416 | 3,634 | 4,239 | Upgrade
|
| EBITDA Margin | 3.00% | 3.04% | 3.15% | 3.15% | 2.97% | 3.82% | Upgrade
|
| D&A For EBITDA | 692.86 | 689.68 | 676.96 | 626.41 | 547.21 | 514.33 | Upgrade
|
| EBIT | 3,900 | 3,923 | 4,053 | 3,790 | 3,087 | 3,724 | Upgrade
|
| EBIT Margin | 2.54% | 2.58% | 2.70% | 2.70% | 2.52% | 3.36% | Upgrade
|
| Effective Tax Rate | 23.36% | 23.40% | 23.45% | 19.47% | 22.45% | 21.89% | Upgrade
|
| Revenue as Reported | 153,354 | 151,810 | 150,140 | 140,424 | 122,407 | 110,860 | Upgrade
|
Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.